Immunotherapy Timing for Cancer

This trial explores whether the timing of immunotherapy affects its success in treating advanced or metastatic solid tumors. Researchers aim to determine if receiving immunotherapy, specifically an immune checkpoint inhibitor, before 11:00 a.m. or after 1:30 p.m. influences its effectiveness, considering the body's natural circadian rhythms. Participants will receive standard immunotherapy and provide blood samples during the study. Individuals with advanced solid tumors, such as lung, kidney, or liver cancer, who have not yet received immunotherapy, might be suitable for this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial requires that you have not used immunosuppressive medication within 28 days before starting the immunotherapy, except for certain low-dose corticosteroids. If you are on other medications, the protocol does not specify if you need to stop them.

Research has shown that immune checkpoint inhibitors, the drugs used in this trial, can effectively treat various types of cancer. These drugs help the immune system attack cancer cells but can also cause side effects.

Studies have found that while many patients tolerate these treatments well, some might experience serious side effects. For instance, the immune system might mistakenly attack healthy organs, such as the heart. Although rare, this can be serious if it occurs.

Researchers are excited about this trial because it explores the timing of immunotherapy administration, which could significantly impact its effectiveness for cancer treatment. Unlike standard approaches where timing is not a focus, this study looks at whether receiving immune checkpoint inhibitors in the morning or afternoon makes a difference. By collecting blood samples and monitoring responses, the trial aims to uncover if timing can enhance the immune system's ability to fight cancer, potentially leading to better outcomes for patients.

Research shows that the timing of immune checkpoint inhibitor treatments affects their effectiveness against cancer. In this trial, participants will be divided into two groups: the AM cohort, receiving treatments before 10:30 AM, and the PM cohort, receiving treatments after 1:30 PM. Studies have found that patients receiving treatments earlier in the day, usually before 4:30 PM, tend to live longer. Specifically, one study noted that people who received treatments later in the day had shorter lifespans. Another report highlighted that those receiving earlier treatments lived between 2.7 to 26.6 months longer. This suggests that the body's internal clock, known as the circadian rhythm, might influence treatment effectiveness.⁶⁷⁸⁹¹⁰